Browsing Radiotherapy and Imaging by author "James, Nicholas"
Now showing items 21-40 of 63
-
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
Andronis, L; Goranitis, I; Pirrie, S; Pope, A; Barton, D; et al. (2017-04)Objective To evaluate the cost-effectiveness of adding zoledronic acid or strontium-89 to standard docetaxel chemotherapy for patients with castrate-refractory prostate cancer (CRPC).Patients and methods Data on resource ... -
Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data.
Clarke, CS; Hunter, RM; Gabrio, A; Brawley, CD; Ingleby, FC; et al. (PUBLIC LIBRARY SCIENCE, 2022-01-01)Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine the value ... -
Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial.
Mintz, HP; Dosanjh, A; Parsons, HM; Hughes, A; Jakeman, A; et al. (BMC, 2020-10-31)BACKGROUND: Bladder cancer outcomes have not changed significantly in 30 years; the BladderPath trial (Image Directed Redesign of Bladder Cancer Treatment Pathway, ISRCTN35296862) proposes to evaluate a modified pathway ... -
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
James, ND; Ingleby, FC; Clarke, NW; Amos, CL; Attard, G; et al. (OXFORD UNIV PRESS, 2022-07-01)BACKGROUND: STAMPEDE previously reported adding upfront docetaxel improved overall survival for prostate cancer patients starting long-term androgen deprivation therapy. We report long-term results for non-metastatic ... -
Exploring the roles of urinary HAI-1, EpCAM & EGFR in bladder cancer prognosis & risk stratification.
Snell, KIE; Ward, DG; Gordon, NS; Goldsmith, JC; Sutton, AJ; et al. (Impact Journals, LLC, 2018-05-18)OBJECTIVES: To investigate whether elevated urinary HAI-1, EpCAM and EGFR are independent prognostic biomarkers within non-muscle-invasive bladder cancer (NMIBC) patients, and have utility for risk stratification to ... -
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial.
James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; Mason, MD; et al. (AMER MEDICAL ASSOC, 2016-03-01)IMPORTANCE: The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. ... -
Gene expression profiling in bladder cancer identifies potential therapeutic targets.
Hussain, SA; Palmer, DH; Syn, W-K; Sacco, JJ; Greensmith, RMD; et al. (SPANDIDOS PUBL LTD, 2017-04-01)Despite advances in management, bladder cancer remains a major cause of cancer related complications. Characterisation of gene expression patterns in bladder cancer allows the identification of pathways involved in its ... -
Health-related quality of life around the time of diagnosis in patients with bladder cancer.
Yu, EY-W; Nekeman, D; Billingham, LJ; James, ND; Cheng, KK; et al. (WILEY, 2019-12-01)OBJECTIVES: To quantify the health-related quality of life (HRQoL) of patients with bladder cancer around the time of diagnosis and to test the hypotheses of a two-factor model for the HRQoL questionnaire QLQ-C30. METHODS: ... -
Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
Choudhury, A; Porta, N; Hall, E; Song, YP; Owen, R; et al. (ELSEVIER SCIENCE INC, 2021-02-01)BACKGROUND: Two radiotherapy fractionation schedules are used to treat locally advanced bladder cancer: 64 Gy in 32 fractions over 6·5 weeks and a hypofractionated schedule of 55 Gy in 20 fractions over 4 weeks. Long-term ... -
Integrated Care in Prostate Cancer (ICARE-P): Nonrandomized Controlled Feasibility Study of Online Holistic Needs Assessment, Linking the Patient and the Health Care Team.
Nanton, V; Appleton, R; Dale, J; Roscoe, J; Hamborg, T; et al. (JMIR PUBLICATIONS, INC, 2017-07-28)BACKGROUND: The potential of technology to aid integration of care delivery systems is being explored in a range of contexts across a variety of conditions in the United Kingdom. Prostate cancer is the most common cancer ... -
Making administrative healthcare systems clinical data the future of clinical trials: lessons from BladderPath
Mintz, HP; Dosanjh, ARS; Parsons, H; Sydes, M; Bryan, RT; et al. (BMJ, 2023-07-01) -
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Gillessen, S; Omlin, A; Attard, G; de Bono, JS; Efstathiou, E; et al. (ELSEVIER, 2015-08-01)The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) ... -
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; et al. (ELSEVIER, 2020-04-01)BACKGROUND: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ... -
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.
Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bossi, A; et al. (ELSEVIER SCIENCE BV, 2018-02-01)BACKGROUND: In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of ... -
Mobile Health Solutions for Prostate Cancer Diagnostics-A Systematic Review.
Moghul, M; Cazzaniga, W; Croft, F; Kinsella, N; Cahill, D; et al. (MDPI, 2023-07-28)Prostate cancer, the most common cause of cancer in men in the UK and one of the most common around the world to date, has no consensus on screening. Multiple large-scale trials from around the world have produced conflicting ... -
MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.
Walker, AK; Karaszi, K; Valentine, H; Strauss, VY; Choudhury, A; et al. (ELSEVIER SCIENCE INC, 2019-07-15)PURPOSE: Organ-confined muscle-invasive bladder cancer is treated with cystectomy or bladder preservation techniques, including radiation therapy. There are currently no biomarkers to inform management decisions and aid ... -
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
Bamias, A; Merseburger, A; Loriot, Y; James, N; Choy, E; et al. (BMJ PUBLISHING GROUP, 2023-01-01)BACKGROUND: Bellmunt Risk Score, based on Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin levels and presence of liver metastases, is the most established prognostic algorithm for patients ... -
Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.
Hussain, SA; Porta, N; Hall, E; Salawu, A; Lewis, R; et al. (ELSEVIER, 2021-02-01)BACKGROUND: BC2001 demonstrated improved local control with the addition of chemotherapy to radiotherapy in 360 patients with muscle-invasive bladder cancer. OBJECTIVE: To establish whether such benefit remained in BC2001 ... -
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
Terrisse, S; Karamouza, E; Parker, CC; Sartor, AO; James, ND; et al. (AMER MEDICAL ASSOC, 2020-02-01)IMPORTANCE: Both α-emitting and β-emitting bone-targeted radioisotopes (RIs) have been developed to treat men with metastatic castration-resistant prostate cancer (CRPC). Only 1 phase 3 randomized clinical trial has ... -
Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial.
Huddart, RA; Hall, E; Lewis, R; Porta, N; Crundwell, M; et al. (ELSEVIER, 2020-02-01)BACKGROUND: BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer, demonstrated improvement of local control and bladder cancer-specific survival from the addition of concomitant ...